If we refer back to the graphs from @Trae 23/4/2018 with increasing cashflow / Sales, in my opinion we can only expect that growth to accelerate with the new distribution channels coming on line later this year.
Some have predicted positive cashflow by Sep 18 4C.
It's quite feasible we will see revenues in excess of $20M some time next financial year.
Cellmid is a Biotech which invests in R&D. Once you exceed $20M in revenue you lose your R&D subsidy,which is a considerable sum. At some point in time Advangen will have to leave the nursery for Cellmid to retain this subsidy.
I wouldn't be surprised if this was part of it, in any case it will need to be addressed at some point in time.
Just some unsubstantiated thoughts.
DYOR
If we refer back to the graphs from @Trae 23/4/2018 with...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
